You are here: Home » Companies » News
Business Standard

GVK Bio licenses database to USFDA for drug repositioning

The material transfer agreement forms the basis of collaboration in drug repositioning, wherein the initial focus will be to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases

BS Reporter  |  Hyderabad 

Hyderabad-based drug R&D and clinical research company, GVK Biosciences Private Limited, today said that it had licensed its database to the US Food and Drug Administration (USFDA) for a collaboration in drug repositioning.

“The material transfer agreement forms the basis of collaboration in drug repositioning, wherein the initial focus will be to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases,” the company said in a statement. The company said it had developed a proprietary ‘drug repositioning platform’ with eight different approaches to address the drug repurposing challenge. The platform will use data from GVK Bio’s proprietary databases such as SAR databases (GOSTAR) and Biomarker database (GOBIOM).

Sreeni Devidas, vice-president (business development) of GVK Bio said that the collaboration with the USFDA was a validation of the utility of GOSTAR in multiple applications.

“Specifically, the ROI (return on investment) generated by the use in drug repositioning is unparalleled. GVK Bio will work with the USFDA to further enhance the repositioning and repurposing work flow and make it available to the entire research community,” he said.

GOSTAR, a manually-curated database containing over 6.5 million compounds, was developed over a span of a decade by a team of over 200 scientists. It is being used globally by pharmaceutical and biotechnology as well as academia, according to the company.

GVK Bio is a research and development organisation providing a broad spectrum of services including clinical research, process R&D to drug firms.

Drug repositioning is gaining traction in the industry and academia and is becoming a mandatory component of the drug development process, said Manni Kantipudi, chief executive officer of GVK Bio.

“We look forward to continue working and collaborating with the FDA with a view to further enhancing the utility of the product (GOSTAR),” he added.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, June 19 2013. 20:30 IST
RECOMMENDED FOR YOU
.